Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
Yes Chris, no speeding tickets, cash calls etc as we all know damn well why it is reacting this way. Its a huge rerate and at £24mn mkt cap its still got legs IMHO to 2, 3 , 4, 5 bag short term IMHO.
Can quite easily see this momentum continuing tomorrow
The other good thing is that there will be no speeding-fines as they have years of money in the bank to support annual expenditure of circa £300k pa!!!!!!
What an excellent position to be in, regardless of the IP.
There is no stock around at all - going to rocket IMHO.
GLA
The bowl forming on the three chart is as pretty as a picture, filling the pattern with blue sky all the way up to £1.75.
Happy days!
Nice gentle rises day by day with traders Taking profits and intraday consolidations will do me just fine.
After a long wait, the time has come, but not just 201 headlines now but Q4 detailed 201 analysis and pitential partners (deal) plus 401 financing update, BC201 update and of course 301 Japanese update - licensing deal?
People waiting to jump ship at 201 headlines, but the journey has just begun so each to their own. I’m following the buffet philosophy or letting your winners run.
Interesting post on the other site:
“Redx is one good comparison. Is valued at GBP 112m today. postrate cancer being such a big problem the market is huge. simialer potential as SNG imo“
I think there will most likely be a big buyer that kick started the rise today, so probably a delayed buy should appear soon.
Happy not to see RNS and should touch 30p today.
GLA
I think if 201 results are what is needed to commercialise, take a look at the size of recent oncology deals. If we can match Xtandi in terms of performance with no side effects and both safe and tolerable, then a deal could be off the charts.
Haven’t mentioned BC201, 301 or 401, plus other IP the BoD have up their sleeves using SPV’s.
Forgot to add positive sentiment and now a strong LTH shareholder base, with the beginnings of positive PR that will be hitting bigger investors and pharma’s radars.
Bankfool, the SP appreciation has been due to cost cutting, new BoD, new product in BC201, advancement with 301 which should lesd to a deal and the imminent big one in the development of 201 to commerciality and the ultimate milestones being achieved. The development adds value to the IP and the one thing VAL has is ridiculous low market cap, under 60 million shares in issue and sound IP with global commerciality and exponential SP growth.
If VAL was Covid-19, it would have a R number of 5 this year and +10 next year!
Sambar, me too and thats the +£2 per share time IMHO.
+30p if no news
+£1 if 201 is as per article “ValiRx ready to step into a new era of development”
I’m hoping news comes on 30th September because at this rate we’ll be 40p before news!
Hardly difficult to predict news, lol, after Suzy confirms 201 headline results EO Q3 on Twitter i.e. within next 7 working days.
First target for me is £1.50 which should before EOY IMHO.
“...... and with the clinical trial results from one of our lead programs due out in Q3 2020, we are ready to grow into a new era of development for the Company.”
Also, l forgot to add that it may happen over several days rather than just a one day spike IMHO. There will be profit taking naturally but like me, l’m also waiting for 301, 401 and BC201 update plus the 201 detail in Q4.
GLA
Not sure if 201 news will happen this week (but happy to wait as l know its coming) but if half decent, the SP could 3-4 bag quite easily from the reactions we have seen with other junior bios in the last 6 months.
Code 1 is rollicks, as is a pattern of previous RNS days. They are simply released when they are ready.
Hey Iceman, do it yourself -suzy is brilliant and you don’t need an intermediary!